John Holaday, QRxPharma
Pain drug developer QRxPharma is approaching a key inflection point. With clinical trials complete and the regulator poised to make a decision on their pain drug MoxDuo in six months' time, there is potential for substantial capital gain.
It is not without risk, however a positive decision will see the share well through our A$1.79 price target.
The firm's Managing Director and CEO, Dr John Holaday, spoke to Morgans Senior Analyst Scott Power about the next steps involved in gaining approval for MoxDuo.
Clients can login to view further research and analysis on QRxPharma.
Print this page